Xenikos receives FDA fast track designation for T-Guard(R) for treating steroid-refractory acute graft-versus-host disease

Xenikos

14 October 2019 - Xenikos is currently preparing to initiate a U.S. pivotal Phase 3 trial.

The Dutch company Xenikos announced today that the U.S. FDA has granted fast track designation to T-Guard, Xenikos' flagship product designed to treat steroid-refractory acute graft-versus-host disease in patients following allogeneic stem cell transplantation. 

Xenikos is currently preparing to initiate a U.S. pivotal Phase 3 trial with T-Guard.

Read Xenikos press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track